

## Bibliographie – Relistor

1. Association canadienne de soins palliatifs. Peut être consulté à l'adresse suivante : <http://www.chpa.net/home.htm>
2. Association canadienne de soins palliatifs – fiche technique : Avril 2008.
3. Burge F et al. Primary care continuity and location of death for those with cancer. *Palliat Med* 2003;6:911-918.
4. Pappagallo M et al. Incidence, prevalence, and management of opioid bowel dysfunction. *Am J Surg* 2001;182 (suppl5): 11S-18S
5. Emanuel EJ et al. Palliative and end-of-life care. In: Kasper DL, Braunwald E, Fauci AS, et al, eds. *Harrison's Principles of Internal Medicine*. 16<sup>th</sup> ed. New York, NY: McGaw-Hill:2005;53-66.
6. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. *Cancer Control* 2004;11:3-9.
7. Hanks G et al. Symptom Management. The management of pain: Opioid Analgesic Therapy (316-341). In *Oxford textbook of Palliative Medicine*, 3<sup>rd</sup> Ed. Oxford University Press, 2003.
8. Goldlist BJ et al. Constipation Can be Deadly. *Canadian Family Physician* 1992;38:2419-2421.
9. Miles CL et al. Laxatives for the management of constipation in palliative care patients. *Cochrane Database of Systematic Reviews* 2006, Issue 4.
10. Jovey D et al. Use of opioid analgesics for the treatment of chronic non-cancer pain – A consensus statement and guidelines from the Canadian Pain Society, 2002. *Pain Research Management* 2003; 8(suppl A):3A-12A.
11. McNicol ED et al. Mu-opioid antagonists for opioid-induced bowel dysfunction. *Cochrane Database Syst Rev* 2008;April16:CD006332.
12. Walsh TD. Prevention of opioid side effects. *J Pain Symptom Manage* 1990;5:362-367.
13. Berde C, Nurko S (editorial). Opioid side effects—mechanism-based therapy. *N Engl J Med* 2008;358:2400-2.
14. Goodheart CR and Leavitt SB. Pain Treatment Topics August 2006. Peut être consulté à l'adresse suivante : <http://www.pain-topics.com>.

15. Thomas J et al. Methylnaltrexone for opioid-induced constipation in advanced illness. *N Engl J Med* 2008;358:2332-43.
16. Ahmedzai SH Boland J. Constipation in people prescribed opioids. *BMJ Clin Evid* 2007;12:1-11.
17. Anon. Methylnaltrexone (MNTX). *Drugs R D* 2006;7(6):374-8.
18. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: A systematic review. *J Pain Symptom Manage* 2007;35:547-65.
19. Berde C, Nurko S. Opioid side effects – mechanism-based therapy [editorial]. *N Engl J Med* 2008;358(22):2400-2.
20. Boyd TA, Israel RJ. Treatment of opioid-induced constipation in hospice patients with methylnaltrexone. [Abstract #8279]. 2004 ASCO Annual Meeting. Peut être consulté à l'adresse suivante : [http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst\\_detail\\_view&confID=26&abstractID=4368](http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=4368) .
21. DeHaven-Hudkins DL, DeHaven RN, Little PJ, Techner LM. The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: Therapeutic opportunities for antagonism at this receptor. *Pharmacology Therapeut* 2008;117:162-87.
22. Santé Canada. Avis de conformité [base de données en ligne]. Peut être consultée à l'adresse suivante : <http://www.nocdatabase.ca/> .
23. Karver SB, Slatkin NE, Thomas J, Israel RJ. Methylnaltrexone treatment of opioid-induced constipation in cancer patients. [abstract #9081] 2007 ASCO Annual Meeting. Peut être consulté à l'adresse suivante : [http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst\\_detail\\_view&confID=47&abstractID=35781](http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=35781) (Consulté le 20 mai 2008).
24. Kurz A, Sessler DI. Opioid-induced bowel dysfunction. *Drugs* 2003;63(7):649-71.
25. Lembo A. Peripheral opioids for functional GI disease: A reappraisal. *Dig Dis* 2006;24:91-8.
26. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-induced bowel dysfunction. *Cochrane Database of Systematic Reviews* 2008, Issue 2. Art. No.: CD006332. DOI: 10.1002/14651858.CD006332.pub2.

27. Murphy BD, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: A peripheral mechanism in humans. *Anesthesiology* 1997;87(4):765-70. Peut être consulté à l'adresse suivante : <http://www.anesthesiology.org/pt/re/anes/fulltext.00000542-199710000-00008.htm;jsessionid=L8XGgB41pr1BTy0L26p1gnJvgynGvjf7CZyTpNVJnHdcNLs2Jjhs!195308708!181195628!8091!-1> .
28. Neyens R, Jackson KC II. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. *J Pain Pall Care Pharmacother* 2007;21(2):27-33.
29. Portenoy RK, Thomas J, Moehl Boatwright ML, *et al.* Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: A double-blind, randomized, parallel group, dosing- ranging study. *J Pain Symptom Manage* 2008;35:458-68.
30. Reichle FM, Conzen PF. Methylnaltrexone, a new peripheral mu-receptor antagonist for the prevention and treatment of opioid-induced extracerebral side effects. *Curr Opin Invest Drugs* 2008;9(1):90-100.
31. Repchinsky C. Compendium des produits et spécialités pharmaceutiques. Association des pharmaciens du Canada, Ottawa, ON. 2008.
32. Shaiova L, Rim F, Friedman D, Jadhi M. A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation. *Pall Supportive Care* 2007;5:161-6.
33. Thomas J. Cancer-related constipation. *Curr Oncol Reports* 2007:278-84.
34. Thomas J. Opioid-induced bowel dysfunction. *J Pain Symptom Manage* 2008;35:103-13.
35. Thomas J, Karver S, Cooney GA, *et al.* Methylnaltrexone for opioid-induced constipation in advanced illness. *N Engl J Med* 2008;358:2332-43.
36. Thomas J, Karver S, Cooney GA, *et al.* Methylnaltrexone for opioid-induced constipation in advanced illness [supplementary appendix]. Peut être consulté à l'adresse suivante : <http://content.nejm.org/cgi/content/full/358/22/2332/DC1>
37. Thomas J, Libman A, Slatkin N, *et al.* A phase II double-blind placebo-controlled trial of methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in advanced medical illness (AMI) .[abstract #8003]. 2005 ASCO Annual Meeting. Peut être consulté à l'adresse suivante : [http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst\\_detail\\_view&confID=34&abstractID=32585](http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=34&abstractID=32585) .

38. Thomas J, Portenoy R, Moehl M, *et al.* A phase II randomized dose-finding trial of methylnaltrexone for the relief of opioid-induced constipation in hospice patients. 2003 ASCO Annual Meeting. Peut être consulté à l'adresse suivante : [http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst\\_detail\\_view&confID=23&abstractID=103785](http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=103785) .
39. Centre collaborateur de l'OMS pour la méthodologie sur l'établissement des statistiques concernant les produits médicamenteux. Codes ATC 2008 [base de données en ligne]. Peut être consultée à l'adresse suivante : <http://www.whocc.no/atcddd/> .
40. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. *Ann Pharmacother* 2007;41:984-93.
41. Yuan CS, Doshan H, Charney MR, *et al.* Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. *J Clin Pharmacol* 2005;45:538-46.
42. Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced constipation. *JAMA* 2000;284(11):1383-4.
43. Yuan CS, Foss JF, O'Connor M, *et al.* Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. *Drug Alcohol Depend* 1998;52:161-5.
44. Yuan CS, Foss JF, O'Connor M, *et al.* Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. *Clin Pharmacol Ther* 2000;67:398-404.
45. Yuan CS, Foss JF, O'Connor M, *et al.* Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. *Pain* 1999;83:631-5.
46. Yuan CS, Foss JF, O'Connor M, *et al.* Methylnaltrexone for reversal of constipation due to chronic methadone use. *JAMA* 2000;283(3):367-72.
47. Yuan CS, Foss JF, O'Connor M, *et al.* Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: A double-blind randomized placebo-controlled trial. *Clin Pharmacol Ther* 1996;59:469-75.
48. Yuan CS, Foss JF, Osinski J, *et al.* The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. *Clin Pharmacol Ther* 1997;61:467-75.

49. Yuan CS, Moss J, Wei G, *et al.* Methylnaltrexone (MNTX) for chronic opioid-induced constipation. 2002 ASCO Annual Meeting. Peut être consulté à l'adresse suivante :  
[http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst\\_detail\\_view&confID=16&abstractID=1501](http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=16&abstractID=1501)
50. Yuan C-S, Wei G, Foss JF, *et al.* Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: A double-blind randomized placebo-controlled trial. *J Pharmacol Exp Therapeut* 2002;300:118-23.
51. Methylnaltrexone (Relistor). London New Drugs Group APC/DTC Briefing Document. July 2008. Peut être consulté à l'adresse suivante :  
<http://www.druginfozone.nhs.uk/Record%20Viewing/viewRecord.aspx?id=594899>
52. Foundation for Medical Practice Education. Constipation. Pharmacological Treatment of Constipation. Appendix 2. Peut être consulté à l'adresse suivante :  
[http://www.fmpe.org/en/documents/doc\\_aids/Constipation-Appendix-2.pdf](http://www.fmpe.org/en/documents/doc_aids/Constipation-Appendix-2.pdf)